XIANYANG, China, Feb. 21,
2018 /PRNewswire/ -- Biostar Pharmaceuticals, Inc. (BSPM)
("Biostar" or "the Company"), a PRC-based manufacturer and marketer
of pharmaceutical and health supplement products
in China for a variety of diseases and conditions, today
announced its plans to launch a new e-commerce sales platform (the
"Sales Platform") following nearly ten months of research and
preparation. The Company intends to complete this platform by the
end of March 2018 and launch it
during the second fiscal quarter of 2018. The Sales Platform will
take a full advantage of various IT trends, including the latest
trending content, sharing economy, innovative promotion of
traditional and new e-commerce, Wechat business distribution
system, etc. The Company will also include its B2C online shopping
mall within the Sales Platform to promote its product line.
"The Sales Platform is a result of our ongoing research and
development effort," said Mr. Wang Ronghua, the Chairman of
Biostar. "This platform is designed to assist the Company in its
effort to expand market share and to increase visibility of our
product line. We intend to complete this platform by the end of
March 2018 and will be officially put
into operation in the second quarter of this year."
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly owned
subsidiary and controlled affiliate in China, develops,
manufactures, and markets pharmaceutical and health supplement
products for a variety of diseases and conditions. For more
information please
visit: http://www.biostarpharmaceuticals.com.
Safe Harbor Relating to the Forward-Looking
Statements
Certain statements in this release concerning our future growth
prospects are forward-looking statements, within the meaning of
Section 27A of the U.S. Securities Act of 1933, as amended, and
Section 21E of the U.S. Securities Exchange Act of 1934, as
amended, which involve a number of risks and uncertainties that
could cause actual results to differ materially from those in such
forward-looking statements. The company uses words and phrases such
as "guidance," "forecasted," "projects," "is expected," "remain
confident," "will" and similar expressions to identify
forward-looking statements in this press release, including
forward-looking statements. Undue reliance should not be placed on
forward-looking information. Forward-looking information is based
on current expectations, estimates and projections that involve a
number of risks, which could cause actual results to vary and in
some instances to differ materially from those anticipated by
Biostar and described in the forward-looking information contained
in this news release. The risks and uncertainties relating to these
statements include, but are not limited to, risks and uncertainties
regarding the Company's ability to complete and launch its sales
platform as planned, and to resume production as anticipated, its
ability to sustain its sales effort going forward, its ability
promptly and effectively to return to the normal production levels,
its ability to retain existing and retain new customers for its
products, the Company's ability to recover its sales and revenue
following the GMP certification renewal, the state of consumer
confidence and market demand or the Company's products, success of
our investments, risks and uncertainties regarding fluctuations in
earnings, our ability to sustain our previous levels of
profitability including on account of our ability to manage growth,
intense competition, wage increases in China, our ability to
attract and retain highly skilled professionals, time and cost
overruns on fixed-price, fixed-time frame contracts, client
concentration, our ability to successfully complete and integrate
potential acquisitions, withdrawal of governmental fiscal
incentives, political instability and regional conflicts and legal
restrictions on raising capital or acquiring companies
outside China. Additional risks that could affect our future
operating results are more fully described in our United States
Securities and Exchange Commission filings including our most
recent Annual Report on Form 10-K for the year ended December
31, 2016, and other subsequent filings. These filings are available
at www.sec.gov. We may, from time to time, make additional
written and oral forward-looking statements, including statements
contained in our filings with the Securities and Exchange
Commission and our reports to shareholders. We do not undertake to
update any forward-looking statements that may be made from time to
time by or on our behalf.
Investor Relations Contact
Please send questions or
comments to:
Biostar Pharmaceuticals, Inc.
Investor Relations Coordinator
+86-29-3368-6638
office@aoxing-group.com
http://www.biostarpharmaceuticals.com
View original
content:http://www.prnewswire.com/news-releases/biostar-pharmaceuticals-inc-announces-plans-to-launch-a-new-ecommerce-sales-platform-300601869.html
SOURCE Biostar Pharmaceuticals, Inc.